Table 1. Cellular immunotherapies.

Target	Tumor type(s)	Reference/Clinical trial(s)
Chimeric antigen receptor–T cell therapies/targets
CD19	B-cell malignancies	18, 19; NCT02975687; NCT02842138; NCT02813837
Mesothelin	Mesothelioma, lung cancer, breast cancer	36, 37; NCT02930993; NCT02706782
L1-CAM	Metastatic neuroblastoma	38; NCT02311621
GD2	Neuroblastoma	25, 39; NCT02107963; NCT02919046
Lewis Y	Myeloid malignancies	24, 40; NCT01716364
EGFRvIII	Brain tumor	NCT01454596
HER2	Colon cancer, HER2-positive lung cancer, malignant glioma, Her2-positive sarcoma	26, 41; NCT00889954; NCT00902044; NCT01109095
CD20	Follicular and mantel cell lymphoma	42, 43; NCT00621452
CEA	Stomach cancer, metastatic adenocarcinoma, breast cancer	44; NCT00673829; NCT00673322
MUC-16/IL-12	Ovarian cancer	45; NCT02498912
WT1	Acute myeloid leukemia, NSCLC, breast, pancreatic, ovarian, colorectal cancer, mesothelioma	27, 28; NCT02408016
CAIX	Renal cell carcinoma	46, 47
FAP	Malignant pleural mesothelioma	48
PSMA	Prostate cancer	NCT00664196; NCT01140373
Kappa light chain (klC)	B-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma	NCT00881920
CD30	Hodgkin’s lymphoma, non-Hodgkin’s lymphomas	NCT01316146
HLA-A1/MAGE1	Melanoma	49, 50
HLA-A2/NY-ESO-1	Sarcoma, melanoma	51
MUC1	Ovarian, breast, pancreas, colorectal, malignant glioma, NSCLC, hepatocellular	52; NCT02587689; NCT02617134; NCT02839954
VEGFR-2	Solid tumors	53, 54; NCT01218867
Adoptive cell therapies
Autologous tumor-infiltrating lymphocyte therapy and IL-2	Metastatic melanoma	14
Dendritic cell vaccine and cytokine- induced killer cell therapy	Hepatobiliary, pancreatic cancer	55
Adoptive T-cell transfer	Metastatic melanoma	15
Dendritic cell-derived exosomes (Dex)	NSCLC, melanoma, colorectal cancer	56– 59
Adoptive CD8 + T cells	KRAS, G12D, colorectal	16
Autologous tumor cell therapy
Vigil EATC	Ovarian cancer, Ewing’s sarcoma, NSCLC, melanoma, triple-negative breast cancer, solid tumors	32– 35

IL, interleukin; NSCLC, non-small cell lung cancer.